Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients

Mitochondrion. 2011 Jul;11(4):623-5. doi: 10.1016/j.mito.2011.03.122. Epub 2011 Apr 7.

Abstract

Coenzyme Q(10) (CoQ(10)) is an essential electron carrier in the mitochondrial respiratory chain and a strong antioxidant. Low CoQ(10) levels have been detected in patients with Fibromyalgia (FM). The purpose of the present work was to assess the effect of CoQ(10) on symptoms of five patients with FM. Patients were evaluated clinically with Visual Analogical Scale of pain (VAS), and Fibromyalgia Impact Questionnaire (FIQ). Patients with CoQ(10) deficiency showed a statistically significant reduction on symptoms after CoQ(10) treatment during 9 months (300 mg/day). Determination of deficiency and consequent supplementation in FM may result in clinical improvement. Further analysis involving more scientifically rigorous methodology will be required to confirm this observation.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antioxidants / therapeutic use
  • Female
  • Fibromyalgia / drug therapy*
  • Humans
  • Lipid Peroxidation
  • Male
  • Middle Aged
  • Mitochondrial Diseases / drug therapy*
  • Oxidative Stress
  • Pain Measurement
  • Patients
  • Plasma / metabolism
  • Reactive Oxygen Species / metabolism
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use
  • Young Adult

Substances

  • Antioxidants
  • Reactive Oxygen Species
  • Ubiquinone
  • coenzyme Q10